IBM, June 2023
In a collaborative study between IBM and Oxford University, researchers demonstrated the capability of generative AI to design new antiviral molecules, specifically for Covid-19. They used the model to generate potential antiviral compounds without prior knowledge of the virus's 3D structure.
This approach resulted in four potential Covid-19 antivirals in a much shorter time than conventional methods, showcasing the potential of generative AI in speeding up drug discovery during crises like pandemics.
